Battle Card: Libra Therapeutics
Martin Gill named CSO. Neurodegenerative pipeline acceleration incoming. Pitch preclinical dev accelerator to cut IND by 20%. Next touch: HTS platform for +30% throughput.
Published on
Do not index
Do not index
🚀 Battle Card: Libra Therapeutics
Quick trigger: Promotes Martin Gill, Ph.D., to Chief Scientific Officer (2025-10-15)
👤 Decision Maker in the News
- Martin Gill, Ph.D., Chief Scientific Officer · 🔗 LinkedIn
💡 Why It Matters
- This Libra Therapeutics sales trigger marks a shift toward acceleration of its neurodegenerative pipeline, signaling increased R&D budgets and partnership opportunities. → Source
🎯 Core Pain Point
- Speeding IND-enabling milestones for TRPML1 candidates
- Scaling small-molecule discovery for autophagy-targeting programs
💰 What to Pitch
- Primary: Preclinical Development Accelerator → Compress IND-enabling studies by up to 20%
- Expansion: Custom High-Throughput Screening Platform → Expand hit-to-lead throughput by 30%
🗺️ Quick Context
- HQ: San Diego, CA
- Employees: ≈ 50
- Rev: ≈ $30 M
- Website: libratherapeutics.com
🤼 Competitive Intel
Which other vendors you’ll probably face to win Libra Therapeutics’s business and capitalize on this Libra Therapeutics sales trigger.
- Charles River — Preclinical CRO
- Unique edge: Broad IND-enabling study portfolio
- Evaluated by VP of Translational Science for toxicology expertise
- Labcorp/Covance — Clinical & Preclinical Services
- Unique edge: Seamless transition from preclinical to clinical
- Evaluated by Head of Clinical Ops for study design alignment
- WuXi AppTec — Integrated R&D Services
- Unique edge: End-to-end small molecule discovery
- Evaluated by CSO for platform consolidation
- Evotec — Drug Discovery Outsourcing
- Unique edge: Deep disease biology partnerships
- Evaluated by Dir. of Research for target validation support
✅ Do-Now Checklist
Connect with Martin Gill, Ph.D. on LinkedIn
Generate email + DM using the Libra Therapeutics sales trigger in your first touch
Schedule follow-ups in CRM (Day 3 & Day 10)
Next Step
Get intel like this daily—no fluff, all pipeline.
Subscribe to NewsletterForLeads
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑compress IND-enabling studies by up to 20%❑
PROOF_METRIC = ❑20% time reduction in IND-enabling studies❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Martin
COMPANY = Libra Therapeutics, Inc.
DEPT = ≈ TBD
SIZE = ≈50
BOTTLENECK = scaling small-molecule discovery
EVENT = Promotes Martin Gill, Ph.D., to Chief Scientific Officer
DETAIL = Promoted to CSO
PAIN = delays in IND-enabling milestones for TRPML1 candidates
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20251015946971&div=41152219
SIM_CO = ≈ TBD
WIN_METRIC = 20% faster IND-enabling studies
NEXT_SIZE = ≈100
EMP_EST = ≈50
REV_EST = ≈$30M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈50-person ≈ TBD
Martin—noticed your ≈ TBD team is ≈50.
That’s when scaling small-molecule discovery slows growth.
We helped ≈ TBD fix this with compress IND-enabling studies by up to 20%.
Result: 20% faster IND-enabling studies.
Quick call?
PS—next bottleneck hits ≈100.
DM ≤45 words, TONE:
Saw your post about Promoted to CSO — delays in IND-enabling milestones for TRPML1 candidates.
compress IND-enabling studies by up to 20%. 20% time reduction in IND-enabling studies.
Quick chat?